An interventional study of Covered Stent and Bare Metal Stent in Atherosclerotic Renal Artery Stenosis, Hypertension and Renal Artery Stenosis, sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital. Not yet recruiting at 15 sites in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-04.
Sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital · Not applicable, Interventional, and Treatment
Atherosclerotic renal artery stenosis is the most common cause of secondary hypertension , increasing the risk of cardiovascular and kidney-related complications. Some small-scale studies have suggested that covered stents are effective and safe, but high-quality evidence from large-scale studies in atherosclerotic renal artery stenosis remains limited.
This study aims to evaluate whether covered stents are more effective than bare metal stents in patients with atherosclerotic renal artery stenosis. Eligible participants will be randomly assigned to receive either a covered stent or a bare metal stent. Patients will be followed for 12 months to assess Changes in eGFR, 24-hour systolic blood pressure, and 24-hour diastolic blood pressure from baseline to 12 months were compared among the groups.
The results of this study may help improve treatment strategies and guide the selection of stent type for patients with this condition.
6,114 studies on the registry are indexed under Hypertension; 912 are open to participants now.
This study's planned enrollment of 150 is above the median of 100 across 4,575 interventional studies indexed under Hypertension.
Browse Hypertension studies →Chinese Academy of Medical Sciences, Fuwai Hospital is the lead sponsor of 147 studies on the registry; 51 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Bare Metal Stent
Device: Covered Stent
Endovascular implantation of a covered stent in the renal artery
Endovascular implantation of a bare metal stent in the renal artery.
Change in eGFR
Change in estimated glomerular filtration rate (eGFR) at 12 months compared with baseline
Time frame: 12 months
Change in 24-Hour Ambulatory Systolic Blood Pressure
Change in 24-Hour Ambulatory Systolic Blood Pressure Compared With Baseline
Time frame: 12 months
Change in 24-Hour Ambulatory Diastolic Blood Pressure
Change in 24-Hour Ambulatory Diastolic Blood Pressure Compared With Baseline
Time frame: 12 months
Change in Office Systolic Blood Pressure
Change in Office Systolic Blood Pressure Compared With Baseline
Time frame: 12 months
Change in Office Diastolic Blood Pressure
Change in Office Diastolic Blood Pressure Compared With Baseline
Time frame: 12 months
Change in Home Systolic Blood Pressure
Change in Home Systolic Blood Pressure Compared With Baseline
Time frame: 12 months
Change in Home Diastolic Blood Pressure
Change in Home Diastolic Blood Pressure Compared With Baseline
Time frame: 12 months
Change in antihypertensive medication burden
Change in antihypertensive medication burden at 12 months compared with pre-procedure levels
Time frame: 12 months
Stent patency
Stent patency at 12 months
Time frame: 12 months
Incidence of perioperative complications
Time frame: 1 month
MACE
Major adverse cardiovascular events (MACE) include cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and hospitalization for heart failure.
Time frame: 12 months
Renal Adverse Events
Renal adverse events include a sustained decline in renal function (≥30% decrease in eGFR from baseline confirmed on repeat measurement), doubling of serum creatinine, initiation of renal replacement therapy (dialysis or kidney transplantation), or progression to end-stage renal disease.
Time frame: 12 months
Plan to share: Yes
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chinese Academy of Medical Sciences, Fuwai Hospital →